These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23072897)

  • 41. Association between asthma control and asthma cost: Results from a longitudinal study in a primary care setting.
    Nguyen HV; Nadkarni NV; Sankari U; Mital S; Lye WK; Tan NC
    Respirology; 2017 Apr; 22(3):454-459. PubMed ID: 27862645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
    Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
    COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.
    Muszbek N; Brixner D; Benedict A; Keskinaslan A; Khan ZM
    Int J Clin Pract; 2008 Feb; 62(2):338-51. PubMed ID: 18199282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.
    Krauth C; Jalilvand N; Welte T; Busse R
    Pharmacoeconomics; 2003; 21(14):1001-24. PubMed ID: 13129414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic aspects of antimicrobial therapy of acute exacerbations of COPD.
    Simoens S; Decramer M; Laekeman G
    Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medication adherence among patients with gout: A systematic review and meta-analysis.
    Scheepers LEJM; van Onna M; Stehouwer CDA; Singh JA; Arts ICW; Boonen A
    Semin Arthritis Rheum; 2018 Apr; 47(5):689-702. PubMed ID: 29198878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.
    Dong D; Tan-Koi WC; Teng GG; Finkelstein E; Sung C
    Pharmacogenomics; 2015 Nov; 16(16):1781-93. PubMed ID: 26554739
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.
    Pradalier A; Auray JP; El Hasnaoui A; Alzahouri K; Dartigues JF; Duru G; Henry P; Lantéri-Minet M; Lucas C; Chazot G; Gaudin AF
    Pharmacoeconomics; 2004; 22(15):985-99. PubMed ID: 15449963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors influencing medication adherence in patients with gout: A descriptive correlational study.
    Chua XHJ; Lim S; Lim FP; Lim YNA; He HG; Teng GG
    J Clin Nurs; 2018 Jan; 27(1-2):e213-e222. PubMed ID: 28618105
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New and Pipeline Drugs for Gout.
    Keenan RT; Schlesinger N
    Curr Rheumatol Rep; 2016 Jun; 18(6):32. PubMed ID: 27097819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum urate levels and gout flares: analysis from managed care data.
    Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
    J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment target and followup measures for patients with gout: a systematic literature review.
    Andrés M; Sivera F; Falzon L; van der Heijde DM; Carmona L
    J Rheumatol Suppl; 2014 Sep; 92():55-62. PubMed ID: 25180129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD.
    Czech M; Opolski G; Zdrojewski T; Dubiel JS; Wizner B; Bolisęga D; Fedyk-Łukasik M; Grodzicki T
    Kardiol Pol; 2013; 71(3):224-32. PubMed ID: 23575775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
    Ruoff G; Edwards NL
    Postgrad Med; 2016 Sep; 128(7):706-15. PubMed ID: 27558643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.